Drogas e Sistema Nervoso Periférico II

Miopatias Tóxicas

Autores

  • Roger Gomes Reis
  • Acary Souza Bulle Oliveira

DOI:

https://doi.org/10.34024/rnc.1999.v7.10427

Palavras-chave:

Miopatia, drogas, toxicidade

Resumo

Um grande número de drogas tem implicado dano muscular ou disfunção da transmissão neuromuscular. Apresenta-se uma revisão dos aspectos clínicos e dos variados mecanismos patofisiológicos, que envolvem tanto efeitos diretos quanto indiretos. Os autores discutem ainda três condições clínicas farmacogenéticas que dependem basicamente de drogas desencadeantes para se manifestarem: as porfirias, a síndrome neuroléptica maligna e a hipertermia maligna.

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Referências

1. Curry SC, Cheng D, Connor D. Drug and toxin induced rhabdomyolysis. Ann Emerg Med, 18:1068-1083, 1989.
2. Bradford RH, Shear CC, Chemos NA, Dujovine C, Downton M et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. Efficacy in modifying plasma lipoproteins and adverse effects in 8245 patients with moderate hypercholesterolemia. Arch Intern Med, 151:43-49, 1991.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344:1383-1389, 1994.
4. Frick MH, Elö O, Haapa K, Heinonem H, Heinsalmi H et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med, 317:1237-1245, 1987.
5. Ayanion JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med, 109:682-686, 1988.
6. Magarian GJ, Lucas LM, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med. 151:1873-1879, 1991.
7. Letin SC, Anderson CF. Nicotinic-acid associated myopathy; a report of three cases. Am J Med, 86:481, 1989.
8. Knitzer RH, Needman BW. Musculoskeletal syndromes associated with treatment of acne. Semin Arthritis Rheumatol, 20:247-251, 1991.
9. Neville HE, Maunder-Sewry CA, McDougall. Chloroquineinduced cytosomes with curvilinear profiles in muscle. Muscle Nerve, 2:376-382, 1979.
10. Tagerud S, Jimanová I, Libelius R. Biochemical and ultrastructural effects of chloroquine on horseradish peroxidase uptake and lysosomal enzyme activities in innervated and denervated mouse skeletal muscle. J Neurol Sci, 75:159-166, 1986.
11. Roth F, Itabashi H, Louie J. Amiodarone toxicity – myopathy and neuropathy. Am Heart J, 119:1225-1229, 1990.
12. Kuncl RW, Wiggins VW. Toxic myopathies. Neurol Clin, 6:593-612, 1988.
13. Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man – clinical, electrophysiological and pathological studies. J Neurol Sci, 10:106-111, 1990.
14. Halla JT, Fallahi S, Koopman WJ. Penicilamine-induced myositis in patients with rheumatoid arthritis. Arthritis Rheum, 29:560-565, 1986.
15. Lewis CA, Boheimer N, Rose P, Jackson G. Myopathy after short term administration of procainamide. Br Med J, 292:593-598, 1986.
16. Wolf S, Goldberg LS, Verity MA. Neuromyopathy and periarteriolitis in a patient receiving levodopa. Arc Intern Med, 136:1055-1057, 1976.
17. Hertzman P, Blevins WL, Mayer B. Association of the eosinophilia-myalgia syndrome with ingestion of tryptophan. N Engl J Med, 322:869-876, 1990.
18. Emslie-Smith AM, Engel AG, Duffy J, Bowles CA. Eosinophilia-myalgia syndrome: immunocytochemical evidence for a T-cell mediated immune effector response. Ann Neurol, 29:524-534, 1991.
19. Comi G, Testa D, Cornelio F. Potassium depletion myopathy – a clinical and morphological study of six cases. Muscle Nerve, 8:17-24, 1985.
20. Knochel P. Neuromuscular manifestations of electrolyte disorders. Am J Med 75:521- 530, 1982.
21. Mihiri C, Baudrimont, Bonne G. Zidovudine myopathy – a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol, 29:606-612, 1991.
22. Simpson DM, Citak KA, Godfrey M, Godbold J, Wolfe DE. Myopathy associated with human immunodeficiency virus and zidovudine – can their effects be differenciated? Neurology, 43:971-976, 1993.
23. Dalakas MC, Illa I, Pezeshkpour GH. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med, 322:1098-1105, 1990.
24. Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychatry, 47:1223-1231, 1984.
25. Witt NJ, Zochodone DW, Bolton CF. Peripheral nerve function in sepsis and multiple organ failure. Chest, 99:176, 1991.
26. Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit – a study of ninety-two patients. Muscle Nerve, 21:610-622, 1998.
27. Rouleau G, Karpati G, Carpenter S. Glucocorticoid excess induces peripheral depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve, 10:428-434, 1987.
28. Sheq JH, Shafiq AS, Shutta HS. Acute myopathy with selective loss of myosin filaments. Neurology, 29:100-106, 1979.
29. Knox AJ, Mascie-Taylor BH, Muers MF. Acute hydrocortisone myopathy in severe asthma. Thorax, 41:411-413, 1986.
30. Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care unit – clinical, electromyographic and pathological aspects. Ann Neurol, 40:645-658, 1996.
31. Hirano M, Ott BR, Raps EC. Acute quadriplegic myopathy – a complication of steroids, nondespolarazing blocking agents or both. Neurology, 42:2082- 2089,1992.
32. Rich MM, Bird SJ, Raps EC. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve, 20:665-672, 1997.
33. Zochodne DW, Ramsay DA, Saly V. Acute necrotizing myopathy of intensive care – electrophysiological studies. Muscle Nerve, 17:285-293, 1994.
34. Faragher MW, Day BJ, Dennett X. Critical care myopathy – an electrophysiological and histological study. Muscle Nerve, 19:516-522, 1996.
35. Latronico N, Fenzi F, Recupero D. Critical illness myopathy and neuropathy. Lancet, 347:1570, 1996.
36. Zochodne DW, Ramsay DA, Robertson DM. A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neurol Sci, 52:387-394, 1993.
37. Rich MM, Pinter MJ, Kraner SD, Barchi RL. Loss of electrical excitability in a animal model of in acute quadriplegic myopathy. Ann Neurol 43:171-178, 1998.
38. Rich MM, Teener JW, Rapps EC, Bird S. Muscle inexcitability with reversible paralysis following steroids and neuromuscular blockade. Muscle Nerve, 21:1231-1237, 1998.
39. Adams RJ, Rivner MH, Salazar J. Effects of oral calcium antagonists on neuromuscular transmission. Neurology, 34:132, 1984.
40. Castlebaum AR, Donofrio PD, Walker FO. Laxative abuse causing hypermagnesemia, quadriparesis and neuromuscular junction defect. Neurology, 39:746-748, 1989.
41. Bashuk RG, Krendell DA. Myasthenia gravis presenting after magnesium administration. Muscle Nerve 13:708-713, 1990
42. Pittinger C, Adamson R. Antibiotic blockade of neuromuscular function. Ann Rev Pharmacol, 12:164-184, 1972.
43. Swifft TR. Disorders of neuromuscular transmission other than myasthenia gravis. Muscle Nerve, 4:334-353, 1984.
44. Wilson RW, Ward MD, Johns TR. Corticosteroids – a direct effect on the neuromuscular transmission. Neurology, 24:1091-1095, 1974.
45. Miller RG, Millner-Brown HS. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology, 36:729-732, 1986.
46. Atchison WD, Adgate L, Baerman CM. Effects of antibiotics on uptake of calcium into isolated nerve terminals. J Pharmacol Exp Ther, 245:394-401, 1988.
47. Rubbo JT, Girgis SD, Sokoll MD. Comparative neuromuscular effects of lincomycin and clindamycin. Anesth, 57:329-334, 1977.
48. Lee DC, Kim Yi, Liu HM. Presynaptic and postsynaptic actions of procainamide on neuromuscular transmission. Muscle Nerve, 6:442-447, 1983.
49. Peterson AH. Association of trimethadione therapy and myasthenia gravis. N Engl J Med, 274:506-507, 1966.
50. So EL, Penry JK. Adverse effects of phenytoin on peripheral nerves and neuromuscular junction – a review. Epilepsia, 22:467-473, 1989.
51. Herishanu Y, Rosemberg P. Beta-blockers and myasthenia gravis. Na Intern Med. 83:834-836, 1973.
52. Granacher RP. Neuromuscular problems associated with lithium. Am J Psychiatry, 134:702, 1987.
53. Drosos AA, Christou L, Galanopolllou V, Tzioufas AG. dPenicillamine induced myasthenia gravis – clinical, serological and genetic findings. Clin Exp Rheumatol, 11:387391, 1993.
54. Kuncl RW, Pestronk A, Drachman DB, Recht-Roland E. The pathophysiology of penicillamine induced myasthenia gravis. Ann Neurol, 20:740-744, 1986.
55. Kauppinem R, Mustajoki. Prognosis of acute porphyria – occurence of acute attacks, precipitating factors and associated diseases. Medicine, 71:1-13, 1992.
56. Moore MR. International review of drugs in acute porphyrias. Int J Biochem, 12:1089-1097, 1982.
57. Disler PB, Bleckenhorst GH, Eales L, Moore MR. Guidelines for drug prescription in patients with acute porphiria. South Afr Med J, 61:656-661, 1982.
58. Suarez JI, Cohen ML, Larken J, Kunch RN, Hricik DE, Daroff RB. Acute intermitent porphyria a clinicopathologic correlation. Neurology, 48:1678-1683, 1997.
59. Lazarus A, Mann SC, Caroff SN. The neuroleptic malignant syndrome and related conditions. Clinical Genetics, 39:6567, 1991.
60. Caroff SN, Mann SC. Neuroleptic malignat syndrome. Med Clin North Am, 77:185-202, 1993.
61. Deuschl G, Oepen G, Hermle L. Neuroleptic malignant syndrome. Pharmacopsychiat 20:168-170, 1989.
62. Otani K, Horiuchi M, Kondo T. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry, 158:850-853, 1991. 63. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry, 146:717-725, 1989.
64. Shalev A, Munitz H. Neuroleptic malignant syndrome – agent and host interaction. Acta Psychiatr Scand, 73:337-347, 1986.
65. Caroff SN, Mann SC, Lazarus A. Neuroleptic malignant syndrome – diagnostic issues. Ann Psychatry, 20:130-147, 1991.
66. Otsu K, Nishida K, Kimura Y, Kusuya T, Hori M. The point mutation Arg 614-cys in the calcium release channel of skeletal sarcoplasmic reticulum is responsible for hypersensivity to caffein and halothane in malignant hyperthermia. J Biol Chem, 269:9413-9415, 1994.
67. Gillard EF, Otsu K, Fuji J. A substitution of cysteine to arginine in the ryanodine receptor is potencially causative of human malignant hyperthermia. Genomics, 11:751-754, 1991.
68. Mickelson JR, Ross JA, Reed BK, Louis CF. Enhanced calcium-induced calcium release by sarcoplasmic reticulum vesicles from malignant hyperthermia suscetible pig muscle. Biochem Biophys Acta, 862:318, 1986.
69. Gronert GA, Mott J, Lee J. Etiology of malignant hyperthermia. Br J Med, 60:253-257, 1988.
70. McLennan DH, Phillips MS. Malignant hyperthermia. Science, 256:789-797, 1993.
71. Vitta CM, Decker A, Jedlika AE, George AL, HeimanPetterson T. Masseter muscle rigity associated with glycine 1306 to alaline mutation in the Na channel alfa subunit gene. Anesthesiology, 82:1097-1103, 1995.

Downloads

Publicado

1999-09-30

Como Citar

Reis, R. G., & Oliveira, A. S. B. (1999). Drogas e Sistema Nervoso Periférico II: Miopatias Tóxicas. Revista Neurociências, 7(3), 115–128. https://doi.org/10.34024/rnc.1999.v7.10427

Edição

Seção

Artigos Originais
Recebido: 2020-03-13
Publicado: 1999-09-30

Artigos mais lidos pelo mesmo(s) autor(es)

1 2 3 4 5 > >>